MOUNTAIN VIEW, Calif.,
Feb. 20, 2014 /PRNewswire/ -- Alexza
Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today its corporate
presentation will be webcast live from two upcoming investor
conferences. The webcast of each presentation may be accessed
from the Investor Relations section of the Alexza Pharmaceuticals
website at www.alexza.com. The conferences and presentation
times are:
- Cowen & Company 34th Annual Health Care
Conference in Boston, MA on
Monday, March 3, 2014 at 4:50 pm ET, direct link to the webcast at
wsw.com/webcast/cowen16/ALXA
- 26th Annual ROTH Conference in Dana Point, CA on Monday, March 10, 2014 at 11:30 am ET, direct link to the webcast at
wsw.com/webcast/roth28/ALXA
A replay of each webcast will be available approximately 24
hours following the presentation and each replay will be available
for 30 days on the Investor Relations section of Alexza's
website.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute
treatment of central nervous system conditions. Alexza's products
are based on the Staccato® system, a hand-held inhaler
designed to deliver a drug aerosol to the deep lung, providing
rapid systemic delivery and therapeutic onset, in a simple,
non-invasive manner.
ADASUVE® (Staccato loxapine) is Alexza's first
commercial product, which was approved by the U.S. Food and Drug
Administration in December 2012 and
by the European Commission in February
2013. Teva Pharmaceuticals USA, Inc. is Alexza's commercial partner for
ADASUVE in the U.S. Grupo Ferrer Internacional, S.A. is Alexza's
commercial partner for ADASUVE in Europe, Latin
America, Russia and the
Commonwealth of Independent States countries.
ADASUVE® and Staccato® are registered
trademarks of Alexza Pharmaceuticals, Inc.
Safe Harbor Statement
The anticipated presentations
will contain forward-looking statements that involve
significant risks and uncertainties. Any statement
describing the Company's expectations or beliefs is a
forward-looking statement, as defined in the Private Securities
Litigation Reform Act of 1995, and should be considered an at-risk
statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of
developing and commercializing drugs, including the ability of
Alexza and our partners, Teva and Ferrer, to effectively and
profitably commercialize ADASUVE, estimated product revenues
and royalties associated with the sale of ADASUVE, the adequacy of
the Company's capital to support the Company's operations, and the
Company's ability to raise additional funds and the potential terms
of such potential financings. The Company's forward-looking
statements also involve assumptions that, if they prove incorrect,
would cause its results to differ materially from those expressed
or implied by such forward-looking statements. These and other
risks concerning Alexza's business are described in additional
detail in the Company's Annual Report on Form 10-K for the year
ended December 31, 2012 and the
Company's other Periodic and Current Reports filed with the
Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and the
Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Logo: http://photos.prnewswire.com/prnh/20140121/SF49110LOGO
SOURCE Alexza Pharmaceuticals, Inc.